| CAT # | Igama lemveliso | Inkcazo |
| CPD100587 | I-Phlorizin | I-Phlorizin, ekwabizwa ngokuba yi-phloridzin, i-glucoside ye-phloretin, i-dihydrochalcone, intsapho ye-bicyclic flavonoids, ephinda ibe yinxalenye yeendlela ezahlukeneyo ze-phenylpropanoid synthesis kwizityalo. I-Phlorizin yi-inhibitor ekhuphisanayo ye-SGLT1 kunye ne-SGLT2 kuba ikhuphisana ne-D-glucose yokubopha kwi-carrier; oku kunciphisa ukuthuthwa kwe-glucose ye-renal, ukunciphisa umthamo we-glucose egazini. I-Phlorizin yaphononongwa njengonyango olunokubakho lonyango lwesifo seswekile esinokubakho, kodwa ukusukela ngoko iye yathatyathelwa indawo zizifaniso zokwenziwa ezikhethiweyo nezithembisayo, ezifana ne-canagliflozin kunye ne-dapagliflozin. |
| CPD0045 | Ipragliflozin | Ipragliflozin, ekwabizwa ngokuba yi-ASP1941, inamandla kwaye ikhetha i-SGLT2 inhibitor kunyango lwe-2 yeswekile. Unyango lwe-Ipragliflozin luphucule ulawulo lwe-glycemic xa yongezwa kunyango lwe-metformin kwaye inokunxulunyaniswa nokuncipha kobunzima kunye nokuncipha koxinzelelo lwegazi xa kuthelekiswa ne-placebo. I-Ipragliflozin ayiphuculi kuphela i-hyperglycemia kodwa kunye nesifo seswekile/ukutyeba-eyayanyaniswa nokungahambi kakuhle kwemetabolism kuhlobo lwe-2 yeempuku zeswekile. Yavunywa ukuba isetyenziswe eJapan ngo-2014 |
| CPD100585 | Tofogliflozin | I-Tofogliflozin, ekwabizwa ngokuba yi-CSG 452, inamandla kwaye ikhetha kakhulu i-SGLT2 inhibitor phantsi kophuhliso lonyango lwe-diabetes mellitus. I-Tofogliflozin iphucula ulawulo lwe-glycemic kunye nokunciphisa ubunzima bomzimba kwizigulane ezinesifo sikashukela sohlobo lwe-2. Idosi yeTofogliflozin ixhomekeke kwidosi ecinezela ukungena kweglucose kwiiseli ze-tubular. I-high glucose exposure (30?mM) ye-4 kunye ne-24? h inyuse kakhulu imveliso yoxinzelelo lwe-oxidative kwiiseli ze-tubular, eziye zacinezelwa ngonyango lwe-tofogliflozin okanye i-antioxidant N-acetylcysteine (NAC). |
| CPD100583 | Empagliflozin | I-Empagliflozin, ekwaziwa njenge-BI10773 (igama lorhwebo iJardiance), lichiza elivunyiweyo kunyango lwe-2 yeswekile kubantu abadala ngo-2014. Yaphuhliswa ngu-Boehringer Ingelheim kunye no-Eli Lilly kunye neNkampani. I-Empagliflozin yi-inhibitor ye-sodium glucose co-transporter-2 (SGLT-2), kwaye ibangela ukuba iswekile egazini ifunxwe zizintso kwaye ikhutshwe kumchamo. I-Empagliflozin yi-inhibitor ye-sodium glucose co-transporter-2 (SGLT-2), efumaneka phantse ngokukodwa kwii-proximal tubules zamacandelo e-nephronic kwizintso. I-SGLT-2 ibika malunga neepesenti ze-90 ze-glucose reabsorption egazini. |
| CPD100582 | I-Canagliflozin | I-Canagliflozin (INN, igama lokurhweba i-Invokana) lichiza lokunyanga isifo seswekile se-2. Yaphuhliswa nguMitsubishi Tanabe Pharma kwaye ithengiswa phantsi kwelayisensi nguJanssen, icandelo likaJohnson & Johnson. I-Canagliflozin yi-inhibitor ye-subtype ye-2 ye-sodium-glucose transport protein (SGLT2), ejongene nobuncinci be-90% ye-glucose reabsorption kwizintso. Ukuthintela esi sithuthi kubangela ukuba iswekile yegazi iphele ngomchamo. NgoMatshi ka-2013, i-canagliflozin yaba yinto yokuqala ye-SGLT2 inhibitor ukwamkelwa e-United States. |
| CPD0003 | Dapagliflozin | I-Dapagliflozin, eyaziwa ngokuba yi-BMS-512148, ichiza elisetyenziselwa ukuphatha uhlobo lwe-2 yeswekile evunyiweyo kwi-2012 yi-FDA. I-Dapagliflozin inqanda i-subtype ye-2 ye-sodium-glucose transport proteins (SGLT2) ejongene nobuncinci be-90% ye-glucose reabsorption kwizintso. Ukuthintela le ndlela yokuthutha kubangela ukuba i-glucose yegazi ikhutshwe ngomchamo. Kulingo lwezonyango, i-dapagliflozin yehlise i-HbA1c nge-0.6 xa ithelekiswa namanqaku epesenti ye-placebo xa yongezwa kwi-metformin. |
